ELECTRONIC ARTS INC. (EA) Stock News

Rosen Law Firm is soliciting investors who purchased Graphic Packaging Holding Company (GPK) securities between February 4, 2025 and February 2, 2026 to join a securities class action lawsuit. The lawsuit alleges that defendants made false and misleading statements regarding inventory management issues, reduced demand, increased costs, and overstated business strength, resulting in unreliable financial guidance. The lead plaintiff deadline is July 6, 2026.

Rosen Law Firm is encouraging investors with losses exceeding $100K in Regencell Bioscience Holdings Limited, Calix, Inc., and Wise Group plc to join securities class action lawsuits. The firm is seeking lead plaintiffs before the June 23, 2026 deadline. Regencell is accused of making false statements regarding market manipulation vulnerability and regulatory risks.

Rosen Law Firm is encouraging investors who purchased securities of FS KKR Capital Corp. (FSK), Calix, Inc. (CALX), and Wise Group plc (WSE) during specified periods to join class action lawsuits. The firm alleges that FS KKR Capital made false statements regarding portfolio restructuring, investment valuations, and distribution strategy durability. The lead plaintiff deadline for the FS KKR case is July 6, 2026.

AeroVironment investors who purchased securities between June 25, 2025 and March 10, 2026 can seek lead plaintiff status in a class action lawsuit. The suit alleges AeroVironment made false statements about competition for the U.S. Space Force's SCAR program contract. After a stop work order and contract termination, the company reported a $151.3 million goodwill impairment and significant operating losses, causing stock declines of 6-17% on successive announcements.

International stocks surged over 30% in 2025, with both the Vanguard FTSE Developed Markets ETF (VEA) and iShares Core MSCI Total International Stock ETF (IXUS) delivering strong returns. VEA offers lower costs and focuses on developed markets, while IXUS provides broader diversification including emerging markets. Both remain attractively valued compared to U.S. equities.

All amounts are unaudited and in Canadian dollars and are based on financial statements prepared in compliance with International Accounting Standard 34 Interim Financial Reporting, unless otherwise noted. Our second quarter 2026 ("Q2 2026") unaudited Interim Consolidated Financial Statements for the period ended April 30, 2026 and Management's Discussion and Analysis ("MD&A"), are available online at www.versabank.com/investor-relations , SEDAR at www.sedarplus.ca and EDGAR at www.sec.gov/edgar . Supplementary Financial Information will also be available on our website at www.versabank.com/investor-relations . LONDON, ON , June 3, 2026 /CNW/ - VersaBank (or the "Bank") (TSX: VBNK (NASDAQ: VBNK ), a North American leader in business-to-business digital banking, as well as technology solutions for cybersecurity, today reported its results for the second quarter ended April 30, 2026. All figures are in Canadian dollars unless otherwise stated. NOTE REGARDING SECOND QUARTER FISCAL 2026 FINANCIAL RESULTS VersaBank's financial results for the second quarter of fiscal 2026 reflect non-core non-interest expenses in the amount of $6.7 million. The non-core non-interest expenses included $4.5 million related to the project costs associated with the Reorganization (see Reorganization note below). Subsequent to the end of the second quarter, the Bank publicly filed a Form S-4 registration statement (the "Registration Statement") with the U.S. Securities and Exchange Commission (the "SEC") in connection with the Reorganization. The Reorganization is intended to enhance shareholder value, mitigate risk and reduce corporate costs over the long term. The Bank expects that the anticipated benefits of the Reorganization will exceed the associated investment however, these expected benefits are subject to various assumptions and uncertainties. As of the end of the second quarter of

Rosen Law Firm is soliciting investors who purchased securities of Immutep Ltd., POET Technologies Inc., and DNOW Inc. to join class action lawsuits. The Immutep case alleges the company made false statements about its TACTI-004 trial prospects, concealing material risks of study failure. The deadline to serve as lead plaintiff in the Immutep case is July 6, 2026.

Rosen Law Firm has filed securities class action lawsuits against POET Technologies, Immutep Ltd., and DNOW Inc., alleging material misstatements and omissions. POET Technologies is accused of misrepresenting its tax status as a PFIC and having an executive violate non-disclosure agreements. Investors with losses exceeding $100,000 are encouraged to join the class actions before the June 29, 2026 lead plaintiff deadline.

The DEA's rescheduling of marijuana from Schedule I to Schedule III in April 2026 was initially seen as historic but has had muted impact. The rescheduling only applies to medical marijuana and provides limited benefits like IRS Section 280E relief. Canopy Growth, a major Canadian cannabis company, cannot fully capitalize on these changes due to its non-controlling interest in its U.S. affiliate Canopy USA, whose results remain unconsolidated. The analyst concludes the rescheduling won't materially affect Canopy Growth soon and does not recommend the stock as a buy.

SEALSQ Corp has acquired a majority equity stake in Wecan Group, increasing its ownership from 28% to majority position, and committed CHF 5 million to accelerate development of AI-powered compliance solutions and post-quantum security infrastructure for financial institutions. The partnership aims to create an integrated quantum-resilient trust platform combining SEALSQ's post-quantum technologies, Wecan Group's compliance expertise, and WISeKey's digital identity ecosystem.

Rosen Law Firm reminds Stellantis N.V. investors of the June 8, 2026 deadline to join a securities class action lawsuit. The lawsuit alleges that Stellantis made false statements about its earnings growth potential and electrification strategy, claiming the company was not well-positioned for battery-powered electric vehicle growth and would need to take significant charges to adjust its priorities.

Rosen Law Firm announces a securities class action lawsuit against Medpace Holdings, Inc. for allegedly making false statements about backlog cancellation rates and providing misleading growth projections. Investors who purchased MEDP stock between April 22, 2025 and February 9, 2026 may be eligible for compensation. The deadline to serve as lead plaintiff is June 8, 2026.

Rosen Law Firm has filed securities class action lawsuits against Phreesia Inc., Zoetis Inc., and ChampionX Corporation on behalf of investors who purchased securities during specified periods. The lawsuits allege that defendants made false or misleading statements regarding business conditions, including slowing demand and reduced visibility in key revenue streams.

Smith+Nephew announced the US launch of its next generation LEAF Patient Monitoring System, a cloud-based platform designed to prevent hospital-acquired pressure injuries (HAPIs). The system uses wearable sensors to monitor patient mobility and improve turning protocol adherence. According to the company, the LEAF system monitors over 150,000 patients annually, reduces HAPI odds by up to 73%, and delivers up to $1.8 million in estimated savings per critical care facility.

TSXV Trading Symbol: VPI VANCOUVER, BC , June 1, 2026 /CNW/ - Vitality Products Inc. (TSXV: VPI ) (the "Company" or "Vitality"), a manufacturer, marketer and distributor of premium vitamins and supplements, is pleased to report its financial results for the fourth quarter and the fiscal year ending January 31, 2026. Year-Over-Year Financial Highlights: 67% decrease in annual net loss to $48,456 9% increase in annual sales to $862,999 73% gross margin of $166,384 in Q4 The financial performance of the Company for its year ended January 31, 2026 is highlighted by a 67% reduction in net loss as the Company continues to make significant strides towards its goal of profitability. The financial results of the Company for its year ended January 31, 2026 show a net loss of $48,456 or $0.00 per share compared to a net loss of $146,063 or $0.00 per share for the same period last year. Sales for the year ended January 31, 2026 increased 9% to $862,999 (2025 - $792,773). The Company's general selling expenses for the year ended January 31, 2026 decreased to $111,765 (2025 - $124,399). The Company's general and administrative expenses for the year ended January 31, 2026 decreased to $542,944 (2025 - $578,830). Vitality fulfilled a key new position in September 2025 of Digital & Amazon Marketing Manager to oversee the Company's digital marketing to support online sales growth including Amazon. As a result, ... Full story available on Benzinga.com

Monopar Therapeutics announced Phase 2 trial results for ALXN1840 (tiomolibdate choline) in treatment-experienced Wilson disease patients. The study demonstrated stabilization or improvement in liver pathology across multiple histologic measures, significant neurologic improvements in UWDRS scores, and improved quality of life. The drug was generally well tolerated with mostly Grade 1-2 adverse events.

Rosen Law Firm is soliciting investors to join securities class action lawsuits against Commvault Systems, ChampionX Corporation, and Regencell Bioscience Holdings. The firm reminds investors of upcoming lead plaintiff deadlines and offers contingency-based legal representation. The lawsuits allege that defendants made materially false statements and concealed adverse facts regarding financial performance.

Rosen Law Firm is reminding investors in Regencell Bioscience Holdings Limited, ChampionX Corporation, and Commvault Systems, Inc. of upcoming lead plaintiff deadlines in securities class action lawsuits. The lawsuits allege that defendants made false or misleading statements regarding market manipulation vulnerabilities, regulatory risks, and other material misstatements that caused investor damages.

Rosen Law Firm has filed a class action lawsuit against Calix, Inc. on behalf of investors who purchased securities between January 28, 2026 and April 21, 2026. The lawsuit alleges that Calix made false and misleading statements regarding its margins, claiming the company benefited from advanced memory component purchasing in Q1 but failed to disclose that supplies were dwindling and the company faced negative margin pressure from rising component costs. Investors who wish to serve as lead plaintiff must file by July 27, 2026.

A securities class action lawsuit has been filed against Gossamer Bio (GOSS) alleging executives concealed placebo response risks in the Phase 3 PROSERA trial for seralutinib. The trial failed to meet its primary endpoint on February 23, 2026, causing an 80% stock price decline. The complaint claims management misled investors about trial design and patient recruitment despite knowing of significant placebo effects, particularly at Latin American sites.

Rosen Law Firm has filed class action lawsuits against AeroVironment, LKQ Corporation, and Babcock & Wilcox Enterprises on behalf of investors who purchased securities during specified periods. The AeroVironment lawsuit alleges the company made false statements regarding competition for U.S. Space Force contracts (SCAR and SCN programs), overstating business prospects. Investors who purchased during the Class Period may be eligible for compensation. The deadline to serve as lead plaintiff in the AeroVironment case is July 27, 2026.

A securities class action lawsuit has been filed against LKQ Corporation for allegedly misrepresenting the benefits and integration prospects of its FinishMaster acquisition. LKQ claimed the acquisition presented 'minimal integration risk' and was a 'highly synergistic opportunity,' but FinishMaster subsequently lost major customers and market share. Investors who purchased LKQ stock between February 27, 2023 and July 23, 2025 may be eligible for compensation. The lead plaintiff deadline is June 22, 2026.

A securities class action lawsuit has been filed against Babcock & Wilcox Enterprises, Inc. (BW) for allegedly making false and misleading statements regarding a Power Generation Contract with Applied Digital. The lawsuit claims that B&W's largest shareholder BRC Group Holdings stood on both sides of the contract and that Applied Digital did not actually need the products/services, raising questions about revenue recognition. Investors who purchased BW securities between November 5, 2025 and March 11, 2026 may be eligible for compensation. The lead plaintiff deadline is June 15, 2026.

Johnson & Johnson announced Phase 3 PROTEUS study results showing ERLEADA® (apalutamide) combined with hormone therapy before and after prostate cancer surgery significantly reduces metastasis/death risk by 20% and increases pathologic complete response rates 9-fold compared to hormone therapy alone in patients with high-risk localized or locally advanced prostate cancer. The findings were presented at ASCO 2026 and published in The New England Journal of Medicine.

Rosen Law Firm has issued deadline notices for securities class action lawsuits against Gossamer Bio, Upstart Holdings, and POET Technologies. Investors with losses exceeding $100K are encouraged to secure counsel before upcoming deadlines. The lawsuits allege false and misleading statements regarding clinical trial design and other material facts.

Rosen Law Firm is notifying investors in Upstart Holdings, Inc. (NASDAQ: UPST) of a June 8, 2026 deadline to join a securities class action lawsuit. The lawsuit alleges that Upstart made false and misleading statements regarding its Model 22 AI risk assessment tool, claiming it frequently overreacted to negative macroeconomic signals, overstated accuracy, and negatively impacted revenue results, rendering the company's 2025 revenue guidance unreliable.

Rosen Law Firm reminds SES AI Corporation investors who purchased securities between January 29, 2025 and March 4, 2026 of the June 26, 2026 lead plaintiff deadline in an ongoing securities class action. The lawsuit alleges that SES AI made materially false statements regarding business prospects, overstated expected results from limited-operation deals, created artificial revenue through circular transactions, and failed to disclose material logistics constraints affecting Q4 2025 revenues and 2026 guidance.

Rosen Law Firm reminds investors in New Era Energy & Digital, Inc. (NUAI) who purchased securities between November 6, 2024 and December 29, 2025 of the June 1, 2026 lead plaintiff deadline in an ongoing securities class action. The lawsuit alleges the company made false statements about its Texas Critical Data Centers project and was involved in a fraudulent scheme regarding oil and gas wells in New Mexico, resulting in misleading financial results.

A securities class action lawsuit has been filed against Immutep Ltd. (NASDAQ: IMMP) for allegedly making false and misleading statements about the TACTI004 trial. The company reportedly concealed negative information about the trial's prospects while publicly stating it was on track, despite internal data suggesting increased risk of failure. Investors who purchased ADRs between March 24, 2025 and March 12, 2026 may be eligible for compensation, with a lead plaintiff deadline of July 6, 2026.

A class action lawsuit has been filed against FS KKR Capital Corp. alleging the company made false statements about portfolio restructuring, investment valuations, and dividend sustainability. The lawsuit follows significant declines in net asset value, increased non-accrual investments, and dividend cuts announced in earnings reports from August 2025 and February 2026. Lead plaintiff motions must be filed by July 6, 2026.